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Introduction: BALB/c mice and C57/BL6 mice have different abilities to recover from ischemia. C57/BL6 mice
display increased vessel collateralization and vascular endothelial growth factor expression with a consequent rapid
recovery from ischemia compared with BALB/c mice. Mesenchymal stem cells (MSCs) are one of the main cell types
that contribute to the recovery from ischemia because, among their biological activities, they produce several
proangiogenic paracrine factors and differentiate into endothelial cells. The objective of this study was to evaluate
whether the MSCs of these two mouse strains have different inductive capacities for recovering ischemic limbs.
Methods: MSCs from these two strains were obtained from the bone marrow, purified and characterized before
being used for in vivo experiments. Limb ischemia was surgically induced in BALB/c mice, and MSCs were injected
on the fifth day. The evolution of limb necrosis was evaluated over the subsequent month. Muscle strength was
assessed on the 30th day after the injection, and then the animals were sacrificed to determine the muscle mass
and perform histological analyses to detect cellular infiltration, capillary and microvessel densities, fibrosis, necrosis
and tissue regeneration.
Results: The MSCs from both strains promoted high level of angiogenesis similarly, resulting in good recovery from
ischemia. However, BALB/c MSCs promoted more muscle regeneration (57%) than C57/BL6 MSCs (44%), which was
reflected in the increased muscle strength (0.79 N versus 0.45 N).
Conclusion: The different genetic background of MSCs from BALB/c mice and C57/BL6 mice was not a relevant
factor in promoting angiogenesis of limb ischemia, because both cells showed a similar angiogenic activity. These
cells also showed a potential myogenic effect, but the stronger effect promoted by BALB/c MSCs indicates that the
different genetic background of MSCs was more relevant in myogenesis than angiogesis.
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Peripheral arterial disease (PAD) obstructs the arteries,
leading to decreased blood flow. PAD is a chronic disease
that affects approximately 3 to 10% of the population [1].
Currently, PAD is primarily treated through the control of
cardiovascular risk factors and the use of antiplatelet drugs,
anticoagulants and vasodilators. Mechanical techniques,
such as angioplasty and surgical revascularization, are re-
served for the more severe cases. Even with these thera-
peutic techniques, 30% of patients can suffer limb
amputation within a year due to the progression of the dis-
ease [2]. These patients depend on the adaptation of pre-
existing collateral vessels (arteriogenesis) or the formation
of new vessels via vasculogenesis or angiogenesis to rescue
tissue oxygenation [3]. Therapeutic neovascularization
using angiogenic factors or stem cells, aimed at rapidly
revascularizing the ischemic area, thus represents a poten-
tial treatment option for regenerating the damaged tissue
and preventing amputations.
Mesenchymal stem cells (MSCs) have the property of
adherence to plastic and the ability to self-renew and dif-
ferentiate into osteoblasts, chondrocytes and adipocytes
[4]. Currently, these cells are known to differentiate into
more different cell types, including skeletal muscle [5,6],
cardiomyocytes and endothelial cells [7-9]. Besides
multipotency, MSCs are capable of suppressing the im-
mune system by secretion of nitric oxide, prostaglandins,
indoleamine 2,3-dioxygenase, IL-6 and others, which
modulate T cells, natural killer cells, dendritic cells and
macrophages [10-12]. These properties have allowed
MSCs to be used as an immunosuppressant for trans-
plantations, autoimmune diseases and graft-versus-host
disease [13].
Therapy using stem cells and progenitor cells has been
widely used in the cardiovascular field, particularly the
injection of bone marrow mononuclear cells [14-18] and
endothelial progenitor cells [19,20]. However, MSCs
seem to be more effective for the treatment of limb is-
chemia [21]. Several in vitro studies [22-24] and in vivo
studies [7,25-27] indicate that MSCs are an important
tool for neovasculogenesis, especially during ischemia,
because the reduction in oxygen levels (hypoxia) induces
MSCs to form capillary-like structures in vitro [28].
When implanted, MSCs differentiate and acquire char-
acteristics of mature endothelial cells [7,29], and they
can also differentiate into vascular smooth muscle cells
and cardiomyocytes [29,30]. However, one of the greatest
potentials of MSCs for neovascularization is related to
their trophic effects. MSCs produce cytokines with para-
crine effects, can prevent fibrosis and apoptosis, can pro-
mote angiogenesis and arteriogenesis and can stimulate
the proliferation and differentiation of tissue-specific
progenitors, thus contributing to tissue repair [31]. The
injection of MSCs from different sources was able toincrease blood flow and vascular density in ischemic
limbs [7,27,32].
Some studies have shown differences in the vascula-
ture of different strains of mice [33-35]. Chalothorn and
colleagues demonstrated that C57/BL6 mice have a
greater density of pre-existing collateral vessels in all tis-
sues and a better recovery rate from ischemia compared
with BALB/c mice [33]. These differences were due to
the increased vessel collateralization, a higher rate of
angiogenesis and increased expression of vascular endo-
thelial growth factor (VEGF; baseline and post ischemia)
and TNFα in the C57/BL6 mice compared with the
BALB/c mice. These differences were due to a poly-
morphism in the cis-acting gene of VEGF-A of BALB/c
mice on chromosome 17 that reduced the transcription
and expression of this gene in response to ischemia.
These observations lead us to question whether MSCs
from different strains will provide a difference in the
treatment of ischemia. To address this question, MSCs
from C57/BL6 mice and BALB/c mice were injected into
the ischemic limbs of BALB/c mice to compare the abil-
ity of limb recovery from ischemia.
Materials and methods
Isolation and characterization of MSCs from mice bone
marrow
Experiments were conducted on 8-week-old BALB/c and
C57/BL6 male mice. All procedures were approved by the
Research Ethics Committee of the Federal University of
São Paulo, Brazil (approval number: CEP 0327/10).
To isolate the MSCs, 8-week-old BALB/c mice and
C57/BL6 mice were sacrificed by cervical dislocation
and the tibia and femur were dissected, and low-glucose
DMEM supplemented with 10% fetal bovine serum, 2
mM L-glutamine, 200 U/ml penicillin, and 200 mg/ml
streptomycin (DMEMc medium) was injected into the
dissected bone to collect bone marrow cells. These cells
were maintained in six-well plates for a few days [36]. Ad-
herent cells were detached with 0.25% trypsin, centrifuged,
resuspended and plated in culture bottles (25 or 75 cm2)
with DMEMc medium at 37°C and with 5% CO2. After
establishing the primary culture, cells were expanded and
maintained until injection. All reagents were obtained
from Invitrogen Co. (Sao Paulo, Brazil).
The differentiation capacity of these cells into adipo-
cytes and osteoblasts was evaluated based on an
established protocol [37]. For osteogenic differentiation,
2 × 105 cells (at passage 8) were plated per well of a six-
well plate. DMEM supplemented with 10–8 mol/l dexa-
methasone, 5 mg/ml ascorbic acid 2-phosphate, 10
mmol/l β-glycerophosphate and 10% fetal bovine serum
were used with medium exchange every 3 days for 3 to 4
weeks. The osteoblasts were stained with 2% Alizarin
Red S, pH 4.1 (Sigma-Aldrich, St Louis, MO, USA). For
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well of a six-well plate containing DMEM supplemented
with 10% fetal bovine serum, 10–8 mol/l dexamethasone,
2.5 μg/ml insulin, and 5 mmol/l rosiglitazone. The cells
(at passage 8) were maintained with medium exchange
every 3 days for 3 to 4 weeks. For staining, the medium
was aspirated, and then cells were fixed with 4% parafor-
maldehyde, washed with PBS and incubated with Oil
Red O (3.75% in 60% isopropyl alcohol) for 5 minutes.
Analysis of vascular endothelial growth factor expression
by real-time PCR
RNA was extracted from MSCs using the RNeasy mini
kit (Qiagen, Hilden, Germany) and treated with DNAse
I (Sigma-Aldrich). The cDNA was synthesized using the
High Capacity Reverse Transcription cDNA kit (Life
Technologies, Sao Paulo, Brazil) and quantitative RT-
PCR assay was performed using SYBR Green QuantiFast
RT-PCR kit (Qiagen) in the Rotor Gene-Q (Qiagen).
The following primers were used to quantify the murine
VEGF level: VEGF_F, AGC CAT CCT CTT CTG CAC
TT; and VEGF_R, TGG GAA GAG AGC TGG AGT
TT. The relative gene expression was calculated by
2–ΔΔCT method. The murine β-actin gene was used to
normalize the data with the following primers: β-actin_F,
GCT CCT CCT GAG CGC AAG; and β-actin_R, CAT
CTG CTG GAA GGT GGA CA. Each reaction was
performed in duplicate, and each experiment was
performed three times.
Induction of hind-limb ischemia and cell therapy
Ischemia was induced surgically in 10-week-old to 12-
week-old BALB/c mice. After being anesthetized with
ketamine (40 mg/kg) and xylazine (10 mg/kg), ischemia
was induced in the right leg by removing the entire fem-
oral artery and closing its branches (deep femoral, epi-
gastric, saphenous and popliteal arteries), based on the
procedure already established in our laboratory [38,39].
Five days after ischemic induction, the mice were
anesthetized again, the quadriceps muscles were exposed
and 5 × 105 cells in 50 μl serum-free DMEM were
injected into the middle of the muscle using a 21 G nee-
dle. MSCs with passage numbers between 7 and 10 were
used in the in vivo experiments.
The mice were divided into the following groups (n = 6
per group): nonischemic animals (N-IS), sham-operated
animals (S), ischemic untreated animals (IS), ischemic ani-
mals treated with MSCs obtained from BALB/c mice
(MSC-Ba) and ischemic animals treated with MSCs
obtained from C57/BL6 mice (MSC-Bl).
Visual assessment and determination of muscle force
The animals were followed-up for 35 days, and a visual
assessment of the limbs was performed weekly based onthe following scale: I, no change; II, nail-blackening; III,
necrosis on toes; and IV, necrosis below the heel.
On the 35th day, before the euthanasia of animals, the
isometric muscle force was determined according to the
method standardized in our laboratory [38,39]. Briefly,
the mouse was anesthetized, the gastrocnemius muscle
was isolated completely while maintaining the vascular
connections and origin of the muscle, and the tendin-
ous insertion of the muscle was isolated and bound to
the force transducer by a suture (iWorx/CB Science,
Inc., Dover, NH, USA). The distal portion of the sciatic
nerve was exposed, connected to bipolar electrodes and
connected to an electrostimulator (Grass S88; Grass
Instruments, Quince, MA, USA). Muscle function was
evaluated by measuring the response of isometric con-
tractions, with adjustment for the tension at rest, to ob-
tain the maximum muscle strength (tetanus), using the
peak voltage curve caused by the electrostimulator.
Muscle strength was recorded and analyzed by
Powerlab® 8/30 (ADInstruments Pty Ltd, Colorado
Springs, CO, USA).
Histological analysis
The animals were euthanized and perfused with an
intravascular injection of PBS. The muscles were then
removed and washed with PBS to wash out the blood.
The quadriceps and gastrocnemius muscles were
weighed on an analytical balance.
The tissues were fixed in 4% paraformaldehyde for 48
hours, dehydrated and embedded in paraffin. Sections of 4
μm were obtained and used for staining with either H & E
to determine the degree of muscle regeneration and the
prevalence of adipocytes and infiltrated cells or Picrosirius
Red to determine the degree of fibrosis. Other sections
were collected on glass slides coated with poly-L-lysine
and subjected to immunohistochemistry using anti-alpha-
actin (1:50) (clone 1A4; Dako A/S, Glostrup, Denmark)
to mark smooth muscle cells and subjected to staining
with biotinylated lectin Griffonia (bandeiraea) simplicifolia
I (Vector Laboratories, Peterborough, UK) to mark the
endothelium and activated macrophages, followed by in-
cubation with streptavidin peroxidase (1:100) (Sigma-
Aldrich) and detection with chromogen diaminobenzidine.
The images obtained using an optical microscope
(Olympus BX60, Shinjuku, Japan) were analyzed digit-
ally. Morphometric analyses of skeletal muscle tissue
were performed on each slide, and at least 10 fields of le-
sions were captured to evaluate necrosis, apoptosis,
muscle regeneration, fibrosis and angiogenesis using
Image Pro Plus (Media Cybernetics, Rockville, USA).
Statistical analysis
GraphPad Prism software (Version 5.01, La Jolla, USA)
was used for all analyses. The VEGF gene expression was
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one-analysis of variance ANOVA followed by post-hoc
Bonferroni test. P <0.05 was considered statistically
significant.
Results and discussion
The different rate of ischemic recovery between C57/BL6
mice and BALB/c mice is a well-known phenomenon
[33-35]. Most animal models of peripheral arterial disease
utilize the BALB/c strain because the C57/BL6 strain has
a rapid recovery after ischemic injury. This rapid recovery
is caused by a genetic difference in the expression of an-
giogenic factors on chromosome 7 [34]. The genetic dif-
ference leads to the increased expression of VEGF (both
basal and after ischemia) and TNFα, greater vessel
collateralization and a higher rate of angiogenesis in C57/
BL6 mice compared with BALB/c mice.
MSCs can secrete significant amounts of cytokines
and growth factors [26,40], which promote new vessel
formation and remodeling of injured tissues. TheseFigure 1 Characterization of bone marrow mesenchymal stem cells. (
(MSCs): ischemic animals treated with MSCs obtained from C57/BL6 mice (MS
mice (MSC-Ba; IV). Adipogenic differentiation was evaluated by the formation
matrix that stains with Alizarin Red provided evidence of osteogenic different
expression analysis. Comparison of expression between MSC-Bl and MSC-Ba wobservations led to the use of these cells for preclinical
studies and clinical trials to treat ischemic limbs and
hearts [29,41-43]. MSCs are present in almost every
organ and tissue of the body [37], but the MSCs from
the bone marrow and adipose tissue are most commonly
used for cell therapy because of their abundance and
easy large-scale production. However, different results
were obtained when MSCs from fat and bone marrow
were utilized to treat ischemic tissues [44], showing that
these cells may act differently depending on their origin
and the microenvironment where they were injected
[31,45]. Understanding the quality of MSCs therefore be-
comes an essential step prior to cell therapy. Because of
the genetics of C57/BL6 mice favors the promotion of
strong angiogenesis, the MSCs from this strain would be
expected to provide greater benefit for the treatment of
limb ischemia than MSCs from BALB/c mice.
To test this hypothesis, mesenchymal cells were ini-
tially extracted from the bone marrow of the femur and
tibia of BALB/c and C57/BL6 mice and characterizeda) Differentiation assay for bone marrow mesenchymal stem cells
C-Bl; I) and ischemic animals treated with MSCs obtained from BALB/c
of lipid vacuoles stained with Oil Red (II, V). The formation of mineralized
iation (III, VI). (b) Vascular endothelial growth factor (VEGF) gene
as performed by quantitative real-time PCR. *P <0.05. Bar: 50 μm.
Figure 2 Therapeutic assessments of the ischemic limbs.
(a), (b) Limb quality was evaluated visually according to the degree
of necrosis. Gastrocnemius muscle force (c) and mass (d) were
determined after 30 days of cell therapy. Is, ischemic group; MSC-Ba,
ischemic animals treated with mesenchymal stem cells (MSCs)
obtained from BALB/c mice; MSC-Bl, ischemic animals treated with
MSCs obtained from C57/BL6 mice; N-IS, nonischemic group;
S, sham-operated group. *P <0.05, n = 6 per group.
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(Figure 1a). Differences were noted between MSCs
from these two strains during culture maintenance: the
growth rate of MSCs derived from C57/BL6 mice (0.8
duplications/day) was higher than that of MSCs derived
from BALB/c mice (0.4 duplications/day). As thegrowth of these cells depends on the presence of vari-
ous growth factors, this difference may indicate the
higher production of cell growth factors by C57/BL6,
which also suggests that C57/BL6 MSCs may bring a
better therapeutic effect for treating ischemia. The dif-
ferent characteristic of MSCs from both mice is
expected because several studies have shown differ-
ences in the characteristics of the MSCs according to
the tissue and species from which they were extracted
[37,46,47].
As commented above, one very important property of
MSCs is their capacity for promoting angiogenesis, and
VEGF is the main growth factor for this process. Com-
paring VEGF expression by MSCs of both mice by real-
time RT-PCR clearly showed higher VEGF expression by
MSCs from C57/BL6 mice than from BALB/c mice,
and these data support the hypothesis that the use of
MSCs from C57/BL6 mice may yield a better outcome
for the treatment of ischemia than MSCs from BALB/c
(Figure 1b).
To test our hypothesis, we used a model of limb ische-
mia that was induced by the complete removal of the
femoral artery and the closing of its branches (deep fem-
oral, epigastric and popliteal arteries). According to Goto
and colleagues, this model is the best representative
model for PAD because it causes severe, stable and uni-
form ischemia, which is essential to evaluate the effect
of the therapy [48]. The mouse strain BALB/c was
chosen for the ischemic model because it has a worse re-
sponse to ischemic induction, with a higher rate of ne-
crosis in the limbs, as demonstrated by Masaki and
colleagues [49], and represents a better model for limb
ischemia. However, very important to note is that this is
not a chronic ischemia model, and is not yet available in
the mouse. Because of the different physiology and size
of diverse animals, it is very difficult to establish a
chronic ischemia model in small rodents.
To treat the ischemic limb of the BALB/c mice, MSCs
were injected 5 days after the induction of ischemia.
This time was chosen because injecting the MSCs in the
first days after injury led to worse results; the rate of ne-
crosis worsened, and many mice suffered amputation
(data not shown). The surgical procedures probably
caused an acute inflammatory reaction, which attracted
neutrophils and macrophages and, consequently, growth
factors and proteases were produced locally. Even
though MSCs have immunosuppressant properties, these
cells also produce growth factors and vessel dilators such
as VEGF and nitric oxide, respectively [11,50], to pro-
mote angiogenesis and tissue repairing. Excess VEGF
and nitric oxide in a tissue is known to be capable of
forming unstable and malfunctioning vessels, which can
lead to vessel disruption and edema [51,52]. The choice
of an adequate moment for cell injection into ischemic
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points to be considered in cell therapy.
Regarding the injection of MSCs from C57/BL6 mice
into the BALB/c limb, there should be no immune re-
sponse because of the immunosuppressive properties of
these cells [53]. This fact is already well established, and
MSCs have been used for immunosuppression in several
clinical studies [54-56].
The effect of acute ischemia was evaluated visually,
which is an easy and non-invasive method. The visual
observation was performed for 30 days, which is a suffi-
cient period for the formation of mature vessels and tis-
sue recovery [32,38,39,49]. During this time, the
ischemic and untreated mice developed more advanced
necrosis; approximately 70% of them reached grade IV
necrosis, and the remaining mice developed grade III ne-
crosis (Figure 2a,b). However, the majority of animals
treated with MSC-Bl or MSC-Ba showed no advanced
necrosis; only 16.7% of the animals developed grade II
necrosis (Figure 2a,b). These data indicate that MSCs
are highly beneficial for ischemia regardless of their
origin.
To assess muscle function, which is a very important
parameter to evaluate the angiogenic and myogenic ef-
fects of cell therapy, muscle strength testing was
performed in the gastrocnemius muscle 30 days after
treatment. The ischemic animals showed a dramaticFigure 3 Histological analysis of limb muscles. Gastrocnemius muscles w
with (a) H & E to assess regenerative (*), necrotic (**) and normal areas and ad
(c) lectin Griffonia and (d) alpha-actin antibody to capillary (arrowheads) dens
leucocytes can be found in necrotic area (**). Macrophages are marked ‘M’ an
20 μm (c, d). n = 10 fields of lesions area per animal. Is, ischemic group; MSC-
MSC-Bl, ischemic animals treated with mesenchymal stem cells (MSCs) obtainreduction in force, which fell from 0.99 N in sham-
operated mice to 0.14 N in ischemic mice, while mice
treated with MSC-Bl reached 0.45 N, and the animals
treated with MSC-Ba experienced the largest recovery,
reaching 0.79 N (Figure 2c). However, no significant differ-
ence of muscle mass was found between these two treated
groups: the treated groups recovered 79% (MSC-Ba) and
74% (MSC-Bl) of their muscle mass compared with the
nonischemic mice (Figure 2d). The stronger muscle
force observed in mice treated with MSC-Ba must
therefore be related to the less adipocytes and greater
regeneration of muscle fibers in comparison with the
MSC-Bl group (Figures 3 and 4a).
To better understand the effect of MSCs in ischemic
muscles at the cellular level, the gastrocnemius muscle
was stained with H & E for a histological evaluation of
the ischemic tissues in terms of the presence of adipocyte,
leukocyte infiltration, cellular degeneration and regener-
ation. The infiltration of leukocytes was significantly re-
duced in treated animals compared with ischemic
animals, varying from 12.8% to 1.4% and 1.1% in the
groups treated with MSC-Bl and MSC-Ba, respectively.
The amount of adipocytes was also reduced from 62.8% in
the ischemic group to 38% and 26% for groups treated
with MSC-Bl and MSC-Ba, respectively. Muscle regener-
ation had a large increase in the treated groups compared
with ischemic group, from 5% in the ischemic group up toere collected after 4 weeks of cell therapy. Tissue samples were stained
ipocyte infiltration (↓), (b) Picrosirius red to fibrotic area (stained in red),
ity and mature vessels (arrow), respectively. High concentration of
d vessels are marked brown. IS, ischemic group. Bar = 50 μm (a, b) and
Ba, ischemic animals treated with MSCs obtained from BALB/c mice;
ed from C57/BL6 mice; S, sham-operated group.
Figure 4 Morphometric analyses of limb muscles. From Figure 3, (a) necrotic, regenerative and normal areas, (b) fibrotic area, (c) capillary
density and (d) matured vessels were determined. More than 50 fields of lesions were counted for each group. A, adipocyte; Is, ischemic group;
LI, Infiltrated leukocyte; MD, muscle degeneration; MR, muscle regeneration; MSC-Ba, ischemic animals treated with MSCs obtained from BALB/c
mice; MSC-Bl, ischemic animals treated with mesenchymal stem cells (MSCs) obtained from C57/BL6 mice. *P <0.05.
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group treated with MSC-Bl. Conversely, cellular degener-
ation remained similar between the ischemic group
(18.9%) and the groups treated with MSC-Bl (15.5%) and
MSC-Ba (15.2%) (Figures 3 and 4a). These results indicate
that treating ischemia with MSCs promoted a remarkable
regeneration of muscle tissue regardless of their origin,
which confirms the visual assessment results but contra-
dicts our initial hypothesis because there was no signifi-
cant difference between the treated groups.
To assess whether the treatment promoted neo-
vascularization, the sectioned slides were stained with
Griffonia lectin, which marks the endothelium of blood
vessels (and activated macrophages, which can be visu-
ally differentiated), and anti-alpha-actin, which marks
alpha-actin of vessel smooth muscle cells. Staining with
Griffonia showed a significantly increased number of ca-
pillaries in both treated groups (684 and 619 vessels/
mm2 in the MSC-Bl and MSC-Ba groups, respectively)
compared with the ischemic group (497 vessels/mm2)
(Figures 3 and 4b), but there was no significant differ-
ence between the treated groups. Immunohistochemistry
for alpha-actin also showed a similar pattern; theischemic group had 40.7 vessels/mm2, and the treated
group had higher densities (57.8 and 51.8 vessels/mm2
in the MSC-Bl and MSC-Ba groups, respectively) (Fig-
ures 3 and 4c). These results show increased vessel dens-
ities after treatment with MSCs, but no difference was
observed between the MSC-Bl and MSC-Ba groups.
Finally, a histological evaluation of fibrosis was
performed with Picrosirius red dye, which stains colla-
gen. In all treated groups, a remarkable reduction in the
fibrotic areas was observed, decreasing from 6.8% in the
ischemic group to 2.8% and 2.6% in groups treated with
MSC-Bl and MSC-Ba, respectively (Figures 3 and 4d).
This reduction is most probably due to mesenchymal
cells, which can prevent collagen deposition and the for-
mation of fibrosis [57] by secreting hepatocyte growth
factor [58]. There was no difference between the two
treated groups, indicating that the genetic difference be-
tween the two strains of mice also did not influence this
parameter.
Conclusion
Our results collectively demonstrate the important role
of MSCs in the recovery of ischemic tissues, regardless
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vent necrosis, decrease inflammatory and adipocytes, in-
crease muscle strength and mass, decrease fibrotic area
and promote neovascularization by increasing the num-
ber of capillaries and larger vessels compared with the
untreated group. However, contrary to our initial hy-
pothesis, the treatment with MSCs from C57/BL6 mice
did not produce better angiogenic results than the treat-
ment with MSCs from BALB/c mice. In terms of
myogenesis, the MSCs from BALB/c mice promoted sig-
nificantly better outcome.
These observations indicate that the amount of growth
factors initially produced by the MSCs is most probably
not the main factor that promotes more angiogenesis
and brings better long-term tissue regeneration. As pre-
viously suggested, perhaps the main role of MSCs in the
injured tissue is to recognize the needs of the micro-
environment and to reprogram local cells to replace
their own damaged tissues, releasing cytokines that
modulate inflammation and immune system [59]. The
similar results obtained with MSCs from BALB/c mice
and C57/Bl6 mice, which have a clear genetic difference
in term of angiogenesis, when treating ischemic tissue
corroborates strongly this idea.
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